Published in Therapie on October 26, 1989
Scrotal temperature is increased in disposable plastic lined nappies. Arch Dis Child (2000) 1.67
Diagnosis, classification, and management of erythema multiforme and Stevens-Johnson syndrome. Arch Dis Child (2000) 1.34
Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol (1993) 7.63
Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol (1993) 5.51
Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg (1996) 5.05
Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol (2007) 4.61
European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol (2009) 3.56
Acute generalized exanthematous pustulosis (AGEP)--a clinical reaction pattern. J Cutan Pathol (2001) 3.41
Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol (1991) 3.29
SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol (2000) 3.06
Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet (1998) 2.89
Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol (1993) 2.89
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol (2007) 2.85
Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol (2000) 2.67
Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985. Arch Dermatol (1990) 2.49
[Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France]. Therapie (1985) 2.41
Linear IgA bullous dermatosis: comparison between the drug-induced and spontaneous forms. Br J Dermatol (2013) 2.38
Melanoma and tumor thickness: challenges of early diagnosis. Arch Dermatol (1999) 2.34
Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol (1995) 2.16
Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS (2001) 2.12
Immunopathology of toxic epidermal necrolysis. Keratinocytes, HLA-DR expression, Langerhans cells, and mononuclear cells: an immunopathologic study of five cases. Arch Dermatol (1992) 2.01
[Drug surveillance and topical drugs]. Ann Dermatol Venereol (1996) 2.01
Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy. Arch Dermatol (1995) 1.98
Safety of roxithromycin. Lancet (1992) 1.94
ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther (2010) 1.83
The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol (2001) 1.79
Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ (1999) 1.79
Chronic radiodermatitis following cardiac catheterisation: a report of two cases and a brief review of the literature. Heart (1999) 1.78
Leg ulcers and hydroxyurea: forty-one cases. Arch Dermatol (1999) 1.77
Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. Br J Cancer (1997) 1.74
Evaluation of clinical criteria for diagnosis of bullous pemphigoid. French Bullous Study Group. Arch Dermatol (1998) 1.70
The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome). Arch Dermatol (1987) 1.69
Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol (1987) 1.62
Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol (2013) 1.60
Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol (1996) 1.58
Neutrophilic dermatoses during granulocytopenia. Arch Dermatol (1995) 1.56
A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis. Br J Dermatol (2002) 1.52
[Fatal cardiac arrhythmia during treatment with cimetidine]. Nouv Presse Med (1978) 1.51
Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol (2004) 1.51
The reconstitution of living skin. J Invest Dermatol (1983) 1.49
[Intravenous pulse methylprednisolone therapy for severe alopecia areata: an open study of 66 patients]. Ann Dermatol Venereol (2003) 1.47
Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol (1990) 1.47
Evidence of a marked 25-hydroxyvitamin D deficiency in patients with congenital ichthyosis. J Eur Acad Dermatol Venereol (2006) 1.45
Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol (1987) 1.45
Cyclosporin A inhibits the antigen-presenting functions of freshly isolated human Langerhans cells in vitro. J Invest Dermatol (1991) 1.44
Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis. Arch Dermatol (1997) 1.43
Dermatomyositis without muscle weakness. Long-term follow-up of 12 patients without systemic corticosteroids. Arch Dermatol (1995) 1.43
Pityriasis rubra pilaris in a patient with human immunodeficiency virus infection. J Am Acad Dermatol (1992) 1.43
Increased serum and blister fluid levels of creatine kinase in patients with toxic epidermal necrolysis. Br J Dermatol (1994) 1.42
[Thalidomide and thrombosis]. Ann Dermatol Venereol (2000) 1.40
Hypothermia related to air-fluidized bed. Intensive Care Med (1991) 1.39
Hypoprothrombinemia and cefotaxime. Am J Gastroenterol (1990) 1.38
Acral persistent papular mucinosis and IgA monoclonal gammopathy: report of a case. Dermatology (1992) 1.38
Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis (1996) 1.34
Delays in diagnosis and melanoma prognosis (I): the role of patients. Int J Cancer (2000) 1.29
Genetic linkage of recessive dystrophic epidermolysis bullosa to the type VII collagen gene. J Clin Invest (1992) 1.29
Study of 39 documented relapses of multibacillary leprosy after treatment with rifampin. Int J Lepr Other Mycobact Dis (1989) 1.28
Drug-induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities. Arch Dermatol (1996) 1.28
Severe cutaneous reactions to self-defense sprays. Arch Dermatol (1993) 1.28
Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol (1996) 1.27
MR imaging in acute infectious cellulitis. Radiology (1994) 1.23
Drugs associated with bullous pemphigoid. A case-control study. Arch Dermatol (1996) 1.23
Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J Invest Dermatol (1991) 1.21
Autosomal recessive lamellar ichthyosis: identification of a new mutation in transglutaminase 1 and evidence for genetic heterogeneity. Hum Mol Genet (1995) 1.20
Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients. Br J Dermatol (2013) 1.18
Psoriatic fibroblasts induce hyperproliferation of normal keratinocytes in a skin equivalent model in vitro. Science (1985) 1.18
Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med (1997) 1.15
Mapping of Papillon-Lefevre syndrome to the chromosome 11q14 region. Eur J Hum Genet (1997) 1.13
Molecular characterization of a human tyrosinase-related-protein-2 cDNA. Patterns of expression in melanocytic cells. Eur J Biochem (1994) 1.12
Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists. Clin Infect Dis (2006) 1.11
Clinicopathologic correlation in erythema multiforme and Stevens-Johnson syndrome. Arch Dermatol (1995) 1.09
Prognostic factors and predictive signs of malignancy in adult dermatomyositis. A study of 32 cases. Arch Dermatol (1990) 1.08
Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome. Br J Dermatol (1998) 1.07
Cell survival and shuttle vector mutagenesis induced by ultraviolet A and ultraviolet B radiation in a human cell line. J Invest Dermatol (1996) 1.07
Non-coherent near infrared radiation protects normal human dermal fibroblasts from solar ultraviolet toxicity. J Invest Dermatol (1998) 1.06
Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol (2000) 1.06
Acute swelling of the limbs: magnetic resonance pictorial review of fascial and muscle signal changes. Eur J Radiol (1999) 1.05
Regression of primary melanoma with metastases. Cancer (1992) 1.04
[Criteria for assessing granulocytic or platelet cytopenia caused by drugs. Results of consensus meetings]. Nouv Rev Fr Hematol (1987) 1.04
HLA-G and NK receptor are expressed in psoriatic skin: a possible pathway for regulating infiltrating T cells? Am J Pathol (2001) 1.04
UVA-induced lipid peroxidation in cultured human fibroblasts. Biochim Biophys Acta (1991) 1.03
Haemolytic streptococcal gangrene and non-steroidal anti-inflammatory drugs. Br Med J (Clin Res Ed) (1985) 1.03
A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol (2007) 1.02
[Oculomotor nerve paralysis with complete ptosis in herpes zoster ophthalmicus: 2 cases]. Ann Dermatol Venereol (1997) 1.01
[100 cases of common rheumatoid polyarthritis, treated with D-penicillamin]. Ann Med Interne (Paris) (1974) 1.01
[French pharmacovigilance database system: examples of utilisation]. Therapie (1996) 1.01
The nitric oxide donors, azide and hydroxylamine, inhibit the programmed cell death of cytokine-deprived human eosinophils. FEBS Lett (1995) 1.00
Sclerodermatous chronic graft-versus-host disease. Analysis of seven cases. J Am Acad Dermatol (1992) 0.99
T-cell receptor-gamma/delta bearing lymphocytes in normal and inflammatory human skin. J Invest Dermatol (1990) 0.99
Acquisition of granzyme B and Fas ligand proteins by human keratinocytes contributes to epidermal cell defense. J Immunol (1997) 0.99
Physicochemical properties and stability of anthralin in model systems and human skin. J Invest Dermatol (1983) 0.99
Micropuncture study of renal phosphorus transport in hypophosphatemic vitamin D resistant rickets mice. Pflugers Arch (1977) 0.99
Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial. Br J Dermatol (2009) 0.99
Delays in diagnosis and melanoma prognosis (II): the role of doctors. Int J Cancer (2000) 0.98